EUVIMEDEUVIMED entdecken
Crossref

Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients

Jiaqi Bo, Baohua Yu, Rui Bi, Xiaoli Xu, Yufan Cheng, Xiaoyu Tu, Qianming Bai, Wentao Yang, Ruohong Shui

Clinical Breast Cancer · 2023-06 · 23 (4) · 436-446

DOI: 10.1016/j.clbc.2023.03.002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Clinical Breast Cancer, 2023-06. Verfasst von Jiaqi Bo und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pathology, Fudan University Shanghai Cancer Center, China; Department of Pathology, Tongji Hospital, School of Medicine, Tongji Univers…. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 15-mal zitiert (Crossref) und nennt 37 Literaturangaben. Gefördert von: Shanghai Science and Technology Development Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND: Few studies have focused on converting ER-low-positive and HER2-low status following neoadjuvant therapy (NAT). We aimed to assess the evolution in ER and HER2 status after NAT in breast cancer patients. PATIENTS AND METHODS: Our study included 481 patients with residual invasive breast cancer after NAT. ER and HER2 status were assessed in the primary tumor and residual disease, and associations between ER and HER2 conversion and clinicopathological factors were explored. RESULTS: In primary tumors, 305 (63.4%) cases were ER-positive (including 36 cases of ER-low-positive), 176 (36.6%) were ER-negative. In residual disease, ER status changed in 76 (15.8%) cases, of which 69 cases switched from positive to negative. ER-low-positive tumors (31/36) were the most likely to change. In primary tumors, 140 (29.1%) tumors were HER2-positive, and 341 (70.9%) were HER2-negative (including 209 cases of HER2-low and 132 cases of HER2-zero). In residual disease, 25 (5.2%) cases had HER2 conversion between positive and negative. Considering HER2-low status, 113 (23.5%) cases had HER2 conversion, mostly driven by cases switching either to or from HER2-low. ER conversion had a positive correlation with pretreatment ER status (r = 0.25; P = .00). There was a positive correlation between HER2 conversion and HER2-targeted therapy (r = 0.18; P = .00). CONCLUSION: Conversion of ER and HER2 status was observed in some breast cancer patients after NAT. Both ER-low-positive and HER2-low tumors showed high instability from the primary tumor to residual disease. ER and HER2 status should be retested in residual disease for further treatment decisions, especially in ER-low-positive and HER2-low breast cancer.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Breast NeoplasmsHumansFemaleNeoadjuvant TherapyEast Asian PeopleErb-b2 Receptor Tyrosine Kinases

Stichwörter der Autor:innen

Clinicopathological factorER-low-positiveHER2-lowRetrospective study

Substanzen

Erb-b2 Receptor Tyrosine Kinases

Autor:innen und Institutionen

  • Department of Pathology, Fudan University Shanghai Cancer Center, China; Department of Pathology, Tongji Hospital, School of Medicine, Tongji University, Shanghai, China.
  • Department of Pathology, Fudan University Shanghai Cancer Center, China; Department of Oncology, Shanghai Medical College, Fudan University, China; Institute of Pathology, Fudan University, Shanghai, China.
  • Department of Pathology, Fudan University Shanghai Cancer Center, China; Department of Oncology, Shanghai Medical College, Fudan University, China; Institute of Pathology, Fudan University, Shanghai, China. Electronic a…

Förderung

  • Shanghai Science and Technology Development Foundation

Zitieren

APA

Bo, J., Yu, B., Bi, R., Xu, X., Cheng, Y., Tu, X., Bai, Q., Yang, W., & Shui, R. (2023). Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients. Clinical Breast Cancer, 23(4), 436-446. https://doi.org/10.1016/j.clbc.2023.03.002

Vancouver

Bo J, Yu B, Bi R, Xu X, Cheng Y, Tu X, et al. Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients. Clinical Breast Cancer. 2023;23(4):436-446. doi:10.1016/j.clbc.2023.03.002

BibTeX
@article{Bo2023,
  author = {Bo, Jiaqi and Yu, Baohua and Bi, Rui and Xu, Xiaoli and Cheng, Yufan and Tu, Xiaoyu and Bai, Qianming and Yang, Wentao and Shui, Ruohong},
  title = {Conversion of ER and HER2 Status After Neoadjuvant Therapy in Chinese Breast Cancer Patients},
  journal = {Clinical Breast Cancer},
  year = {2023},
  volume = {23},
  number = {4},
  pages = {436--446},
  doi = {10.1016/j.clbc.2023.03.002}
}
Kostenlos starten →